Pharmacodynamic aspects of intraperitoneal cytotoxic therapy

Peritoneal Carcinomatosis: A Multidisciplinary Approach

Volumn , Issue , 2007, Pages 195-214

  Ceelen, Wim P ^a   Påhlman, Lars ^b   Mahteme, Haile ^b  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ANIMAL; HUMAN; HYPERTHERMIC THERAPY; INFUSION; METABOLISM; METHODOLOGY; NEOPLASM; PERITONEUM; REGIONAL PERFUSION; REVIEW; TISSUE DISTRIBUTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; HUMANS; HYPERTHERMIA, INDUCED; INFUSIONS, PARENTERAL; NEOPLASMS; PERITONEUM; TISSUE DISTRIBUTION;

EID: 34548388025     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-48993-3_12     Document Type: Chapter

References (79)

1. Minchinton AI, Tannock IF. (2006) Drug penetration in solid tumours. Nat Rev Cancer 6(8):583-592
2. Tannock IF, Lee CM, Tunggal JK, Cowan DSM, Egorin MJ. (2002) Limited penetration of anticancer drugs through tumor tissue: A potential cause of resistance of solid tumors to chemotherapy. Clin Cancer Res 8(3):878-884
3. Sugarbaker PH, Mora JT, Carmignani P, Stuart OA, Yoo D. (2005) Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy. Oncologist 10(2):112-122
4. Barlogie B, Corry PM, Drewinko B. (1980) Invitro Thermochemotherapy of Human-Colon Cancer-Cells with Cis-Dichlorodiammineplatinum(Ii) and Mitomycin-C. Cancer Res 40(4):1165-1168
5. Fujimoto S, Takahashi M, Kobayashi K, Nagano K, Kure M, Mutoh T, Ohkubo H. (1992) Cytohistologic Assessment of Antitumor Effects of Intrap-eritoneal Hyperthermic Perfusion with Mitomycin-C for Patients with Gastric-Cancer with Peritoneal Metastasis. Cancer 70(12):2754-2760
6. Van Ruth S, Verwaal VJ, Hart AAM, Van Slooten GW, Zoetmulder FAN. (2003) Heat penetration in locally applied hyperthermia in the abdomen during intra-operative hyperthermic intraperitoneal chemotherapy. Anticancer Res 23(2B):1501-1508
7. Jacquet P, Averbach A, Stephens AD, Stuart OA, Chang D, Sugarbaker PH. (1998) Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: Pharmacokinetic studies. Oncology 55(2):130-138
8. van Ruth S, Verwaal VJ, Zoetmulder F. (2003) Pharmacokinetics of intraperi-toneal mitomycin C. Surg Oncol Clin N Am 12:771-780
9. van Ruth S, Mathot RAA, Sparidans RW, Beijnen JH, Verwaal VJ, Zoetmulder FAN. (2004) Population pharmacokinetics and pharmacodynam-ics of mitomycin during intraoperative hyperthermic intraperitoneal chemotherapy. Clinical Pharmacokinetics 43(2):131-143
10. Sugarbaker PH, Stuart OA, Carmignani CP. (2006) Pharmacokinetic changes induced by the volume of chemotherapy solution in patients treated with hyperthermic intraperitoneal mitomycin C. Cancer Chemother Pharmacol 57(5):703-708
11. Markman M, Walker JL. (2006) Intraperitoneal chemotherapy of ovarian cancer: A review, with a focus on practical aspects of treatment. J Clin Oncol 24(6):988-994
12. Rossi CR, Foletto M, Mocellin S, Pilati P, De Simone M, Deraco M, Cava-liere F, Palatini P, Guasti F, Scalerta R, Lise M. (2002) Hyperthermic Intra-operative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis-Phase I study. Cancer 94(2):492-499
13. Cho HK, Lush RM, Bartlett DL, Alexander HR, Wu PC, Libutti SK, Lee KB, Venzon DJ, Bauer KS, Reed E, Figg WD. (1999) Pharmacokinetics of cis-platin administered by continuous hyperthermic peritoneal perfusion (CHPP) to patients with peritoneal carcinomatosis. J Clin Pharmacol 39(4):394-401
14. Leopold KA, Oleson JR, Clarkepearson D, Soper J, Berchuck A, Samulski TV, Page RL, Blivin J, Tomberlin JK, Dewhirst MW. (1993) Intraperitoneal Cisplatin and Regional Hyperthermia for Ovarian-Carcinoma. Int J Radiat Oncol Biol Physics 27(5):1245-1251
15. Ma GY, Bartlett DL, Reed E, Figg WD, Lush RM, Lee KB, Libutti SK, Alexander HR. (1997) Continuous hyperthermic peritoneal perfusion with cisplatin for the treatment of peritoneal mesothelioma. Cancer J Sci Am 3(3):174-179
16. Zeamari S, Floot B, Van der Vange N, Stewart FA. (2003) Pharmacokinetics and pharmacodynamics of cisplatin after Intraoperative Hyperthermic Intrap-eritoneal Chemoperfusion (HIPEC). Anticancer Res 23(2B):1643-1648
17. Los G, Sminia P, Wondergem J, Mutsaers PHA, Havemen J, Huinink DT, Smals O, Gonzalezgonzalez D, McVie JG. (1991) Optimization of Intraperi-toneal Cisplatin Therapy with Regional Hyperthermia in Rats. Eur J Cancer 27(4):472-477
18. Los G, Vanvugt MJH, Pinedo HM. (1994) Response of Peritoneal Solid Tumors after Intraperitoneal Chemohyperthermia Treatment with Cisplatin or Carboplatin. Br J Cancer 69(2):235-241
19. van de Vaart PJM, van der Vange N, Zoetmulder FAN, van Goethem AR, van Tellingen O, Huinink WWT, Beijnen JH, Bartelink H, Begg AC. (1998) In-traperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: Pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer 34(1):148-154
20. Czejka M, Jager W, Schuller J, Teherani D. (1991) Pharmacokinetics of Car-boplatinum in Serum and Intraperitoneal-Fluid after Intraperitoneal Administration. Arch Pharm (Weinheim) 324(3):183-184
21. Miyagi Y, Fujiwara K, Kigawa J, Itamochi H, Nagao S, Aotani E, Terakawa N, Kohno I. (2005) Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of car-boplatin-A Sankai Gynecology Study Group (SGSG) study. Gynecol Oncol 99(3):591-596
22. Los G, Verdegaal EME, Mutsaers PHA, McVie JG. (1991) Penetration of Carboplatin and Cisplatin into Rat Peritoneal Tumor Nodules after Intraperi-toneal Chemotherapy. Cancer Chemother Pharmacol 28(3):159-165
23. Los G, Smals OAG, Vanvugt MJH, Vandervlist M, Denengelse L, McVie JG, Pinedo HM. (1992) A Rationale for Carboplatin Treatment and Abdominal Hyperthermia in Cancers Restricted to the Peritoneal-Cavity. Cancer Res 52(5):1252-1258
24. Ohno SJ, Siddik ZH, Baba H, Stephens LC, Strebel FR, Wondergem J, Khokhar AR, Bull JMC. (1991) Effect of Carboplatin Combined with Whole-Body Hyperthermia on Normal Tissue and Tumor in Rats. Cancer Res 51(11):2994-3000
25. Steller MA, Egorin MJ, Trimble EL, Bartlett DL, Zuhowski EG, Alexander HR, Dedrick RL. (1999) A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer. Cancer Chemother Pharmacol 43(2):106-114
26. Formenti SC, Shrivastava PN, Sapozink M, Jozsef G, Chan KK, Jeffers S, Morrow PC, Muggia FM. (1996) Abdomino-pelvic hyperthermia and intrap-eritoneal carboplatin in epithelial ovarian cancer: Feasibility, tolerance and pharmacology. Int J Radiat Oncol Biol Phys 35(5):993-1001
27. Rietbroek RC, vandeVaart PJM, Haveman J, Blommaert FA, Geerdink A, Bakker PJM, Veenhof CHN. (1997) Hyperthermia enhances the cytotoxicity and platinum-DNA adduct formation of lobaplatin and oxaliplatin in cultured SW 1573 cells. J Cancer Res Clin Oncol 123(1):6-12
28. Pestieau SR, Belliveau JF, Griffin H, Stuart OA, Sugarbaker PH. (2001) Pharmacokinetics of intraperitoneal oxaliplatin: Experimental studies. J Surg Oncol 76(2):106-114
29. Elias D, Bonnay A, Puizillou JM, Antoun S, Demirdjian S, El Otmany A, Pignon JP, Drouard-Troalen L, Ouellet JF, Ducreux M. (2002) Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol 13(2):267-272
30. Rouers A, Laurent S, Detroz B, Meurisse M. (2006) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal car-cinomatosis: Higher complication rate for oxaliplatin compared to mitomycin C. Acta Chir Belg 106(3):302-306
31. Bos AME, De Vos F, de Vries EGE, Beijnen JH, Rosing H, Mourits MJE, van der Zee AGJ, Gietema JA, Willemse PHB. (2005) A phase I study of in-traperitoneal topotecan in combination with intravenous carboplatin and paclitaxel in advanced ovarian cancer. Eur J Cancer 41(4):539-548
32. Plaxe SC, Christen RD, O'Quigley J, Braly PS, Freddo JL, McClay E, Heath D, Howell SB. (1998) Phase I and pharmacokinetic study of intraperitoneal topotecan. Invest New Drugs 16(2):147-153
33. Teicher BA, Holden SA, Khandakar V, Herman TS. (1993) Addition of a Topoisomerase-I Inhibitor to Trimodality Therapy [Cis-Diamminedi- chloroplatinum(Ii) Heat Radiation] in a Murine Tumor. J Cancer Res Clin Oncol 119(11):645-651
34. Hermisson M, Weller M. (2000) Hyperthermia enhanced chemosensitivity of human malignant glioma cells. Anticancer Res 20(3A):1819-1823
35. Guichard S, Chatelut E, Lochon I, Bugat R, Mahjoubi M, Canal P. (1998) Comparison of the pharmacokinetics and efficacy of irinotecan after administration by the intravenous versus intraperitoneal route in mice. Cancer Chemother Pharmacol 42(2):165-170
36. Sumiyoshi K, Strebel FR, Rowe RW, Bull JMC. (2003) The effect of whole-body hyperthermia combined with 'metronomic' chemotherapy on rat mammary adenocarcinoma metastases. Int J Hyperthermia 19(2):103-118
37. Mohamed F, Marchettini P, Stuart OA, Urano M, Sugarbaker PH. (2003) Thermal enhancement of new chemotherapeutic agents at moderate hyper-thermia. Ann Surg Oncol 10(4):463-468
38. Elias D, Matsuhisa T, Sideris L, Liberale G, Drouard-Troalen L, Raynard B, Pocard M, Puizillou JM, Billard V, Bourget P, Ducreux M. (2004) Heated intra-operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and tolerance. Ann Oncol 15(10):1558-1565
39. Markman M. (1993) Salvage Intraperitoneal Chemotherapy for Ovarian-Cancer-a Possible Role for Mitoxantrone. Eur J Cancer 29A(9): 1225-1226
40. Wiedemann G, Mella O, Roszinski S, Weiss C, Wagner T. (1992) Hyper-thermia Enhances Mitoxantrone Cytotoxicity on Human Breast-Carcinoma and Sarcoma Xenografts in Nude-Mice. Int J Radiat Oncol Biol Physics 24(4):669-673
41. Nicoletto MO, Padrini R, Galeotti F, Ferrazzi E, Cartei G, Riddi F, Palumbo M, De Paoli M, Corsini A. (2000) Pharmacokinetics of intraperitoneal hyper-thermic perfusion with mitoxantrone in ovarian cancer. Cancer Chemother Pharmacol 45(6):457-462
42. Jacquet P, Averbach A, Stuart OA, Chang D, Sugarbaker PH. (1998) Hyper-thermic intraperitoneal doxorubicin: pharmacokinetics, metabolism, and tissue distribution in a rat model. Cancer Chemother Pharmacol 41(2):147-154
43. Pilati P, Mocellin S, Rossi CR, Scalerta R, Alaggio R, Giacomelli L, Geroni C, Nitti D, Lise M. (2003) Doxorubicin activity is enhanced by hyperthermia in a model of ex vivo vascular perfusion of human colon carcinoma. World J Surg 27(6):640-646
44. Deraco M, De Simone M, Rossi CR, Cavaliere F, Difilippo F, Scuderi S, Pilatti P, Kusamura S. (2003) An Italian multicentric phase 11 study on peri-tonectomy and intra peritoneal hyperthermic perfusion (IPHP) to treat patients with peritoneal mesothelioma. J Exp Clin Cancer Res 22(4):41-45
45. Kusamura S, Deraco M, Baratti D, Inglese MG, Costanzo P, Favaro M, Manzi R, Gavazzi C. (2003) Cytoreductive surgery followed by intra peritoneal hyperthermic perfusion in the treatment of peritoneal surface malignancies: Morbidity and mortality with closed abdomen technique. J Exp Clin Cancer Res 22(4):207-212
46. Rossi CR, Deraco M, De Simone M, Mocellin S, Pilati P, Foletto M, Cavaliere F, Kusamura S, Gronchi A, Lise M. (2004) Hyperthermic intraperitoneal intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis-Clinical outcome and prognostic factors in 60 consecutive patients. Cancer 100(9):1943-1950
47. Takemoto M, Kuroda M, Urano M, Nishimura Y, Kawasaki S, Kato H, Okumura Y, Akaki S, Kanazawa S, Asaumi J, Joja I, Hiraki Y. (2003) The effect of various chemotherapeutic agents given with mild hyperthermia on different types of tumours. Int J Hyperthermia 19(2):193-203
48. Harada S, Ping L, Obara T, Oikawa H, Miyata M, Matsuo M, Takahashi T, Yanagisawa T. (1995) The Antitumor Effect of Hyperthermia Combined with Fluorouracil and Its Analogs. Radiat Res 142(2):232-241
49. Vaillant JC, Nordlinger B, Deuffic S, Arnaud JP, Pelissier E, Favre JP, Jaeck D, Fourtanier G, Grandjean JP, Marre P, Letoublon C. (2000) Adjuvant intraperitoneal 5-fluorouracil in high-risk colon cancer-A multicenter phase III trial. Ann Surg 231(4):449-456
50. Nordlinger B, Rougier P, Arnaud JP, Debois M, Wils J, Ollier JC, Grobost O, Lasser P, Wals J, Lacourt J, Seitz JF, dos Santos JG, Bleiberg H, Mackiewickz R, Conroy T, Bouche O, Morin T, Baila L, van Cutsem E, Bedenne L. (2005) Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II-III colorectal cancer: a multicen-tre randomised controlled phase III trial. Lancet Oncol 6(7):459-468
51. Mahteme H, Larsson B, Sundin A, Khamis H, Graf W. (2004) Uptake of 5-fluorouracil (5-FU) in peritoneal metastases in relation to the route of drug administration and tumour debulking surgery: an autoradiographic study in the rat. Eur J Cancer 40(1):142-147
52. Hofstra LS, Bos AME, de Vries EGE, van der Zee AGJ, Willemsen ATM, Rosing H, Beijnen JH, Mulder NH, Aalders JG, Willemse PHB. (2002) Kinetic modeling and efficacy of intraperitoneal paclitaxel combined with intravenous cyclophosphamide and carboplatin as first-line treatment in ovarian cancer. Gynecol Oncol 85(3):517-523
53. Markman M, Reichman B, Hakes T, Lewis JL, Jones W, Rubin S, Barakat R, Curtin J, Almadrones L, Hoskins W. (1992) Impact on Survival of Surgically Defined Favorable Responses to Salvage Intraperitoneal Chemotherapy in Small-Volume Residual Ovarian-Cancer. J Clin Oncol 10(9):1479-1484
54. Kuh HJ, Jang SH, Wientjes MG, Weaver JR, Au JLS. (1999) Determinants of paclitaxel penetration and accumulation in human solid tumor. J Pharmacol Exp Ther 290(2):871-880
55. Knox JD, Mitchel REJ, Brown DL. (1991) Effects of Hyperthermia on Micro-tubule Organization and Cytolytic Activity of Murine Cytotoxic Lymphocytes-T. Exp Cell Res 194(2):275-283
56. Michalakis J, Georgatos SD, Romanos J, Koutala H, Georgoulias V, Tsiftsis D, Theodoropoulos PA. (2005) Micromolar taxol, with or without hyperther-mia, induces mitotic catastrophe and cell necrosis in HeLa cells. Cancer Chemother Pharmacol 56(6):615-622
57. Rietbroek RC, Katschinski DM, Reijers MHE, Robins HI, Geerdink A, Tutsch K, dOleire F, Haveman J. (1997) Lack of thermal enhancement for taxanes in vitro. Int J Hyperthermia 13(5):525-533
58. Leal BZ, Meltz ML, Mohan N, Kuhn J, Prihoda TJ, Herman TS. (1999) Interaction of hyperthermia with Taxol in human MCF-7 breast adenocarcinoma cells. Int J Hyperthermia 15(3):225-236
59. Schrump DS, Zhai SP, Nguyen DM, Weiser TS, Fisher BA, Terrill RE, Flynn BM, Duray PH, Figg WD. (2002) Pharmacokinetics of paclitaxel administered by hyperthermic retrograde isolated lung perfusion techniques. J Thorac Cardiovasc Surg 123(4):686-694
60. Othman T, Goto S, Lee JB, Taimura A, Matsumoto T, Kosaka M. (2001) Hyperthermic enhancement of the apoptotic and antiproliferative activities of paclitaxel. Pharmacology 62(4):208-212
61. Cividalli A, Cruciani G, Livdi E, Pasqualetti P, Danesi DT. (1999) Hyper-thermia enhances the response of paclitaxel and radiation in a mouse adeno-carcinoma. Int J Radiat Oncol Biol Phys 44(2):407-412
62. Zoul Z, Filip S, Melichar B, Dvorak J, Odrazka K, Petera J. (2004) Weekly paclitaxel combined with local hyperthermia in the therapy of breast cancer locally recurrent after mastectomy-a pilot experience. Onkologie 27(4):385-388
63. Orlando M, Huertas E, Salum G, Loza J, Colo F, Vilanova M, Chacon M, Medina L, Chacon RD. (1998) Intraperitoneal Hyperthermic chemotherapy (IPHC) as consolidation treatment for ovarian cancer in pathological complete response. Proc Am Soc Clin Concol 17:abstract 1432
64. Yonemura Y, Bandou E, Sawa T, Yoshimitsu Y, Endou Y, Sasaki T, Sugar-baker PH. (2006) Neoadjuvant treatment of gastric cancer with peritoneal dissemination. Eur J Surg Oncol 32(6):661-665
65. Morgan RJ, Doroshow JH, Synold T, Lim D, Shibata S, Margolin K, Schwarz R, Leong L, Somlo G, Twardowski P, Yen Y, Chow W, Lin P, Paz B, Chu D, Frankel P, Stalter S. (2003) Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: Dose-limiting toxicity and pharmacokinetics. Clin Cancer Res 9(16):5896-5901
66. de Bree E, Rosing H, Beijnen JH, Romanos J, Michalakis J, Georgoulias V, Tsiftsis DD. (2003) Pharmacokinetic study of docetaxel in intraoperative hyperthermic i.p. chemotherapy for ovarian cancer. Anticancer Drugs 14(2):103-110
67. Gardner SN. (2000) A mechanistic, predictive model of dose-response curves for cell cycle phase-specific and-nonspecific drugs. Cancer Res 60(5):1417-1425
68. Vail DM, Amantea MA, Colbern GT, Martin FJ, Hilger RA, Working PK. (2004) Pegylated liposomal doxorubicin: Proof of principle using preclinical animal models and pharmacokinetic studies. Semin Oncol 31(6):16-35
69. Aoki H, Kakinuma K, Morita K, Kato M, Uzuka T, Igor G, Takahashi H, Tanaka R. (2004) Therapeutic efficacy of targeting chemotherapy using local hyperthermia and thermosensitive liposome: evaluation of drug distribution in a rat glioma model. Int J Hyperthermia 20(6):595-605
70. Nyman DW, Campbell KJ, Hersh E, Richardson K, Patrick K, Trieu V, Desai N, Von Hoff DD. (2004) A phase I trial of ABI-007, nanoparticle paclitaxel, administered to patients with advanced non-hematologic malignancies. J Clin Oncol 22(14):133s-133s
71. Lindner P, Heath D, Howell S, Naredi P, Hafstrom L. (1996) Vasopressin modulation of peritoneal, lymphatic, and plasma drug exposure following in-traperitoneal administration. Clin Cancer Res 2(2):311-317
72. Jain RK. (2001) Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med 7(9):987-989
73. Jain RK. (1989) Delivery of Novel Therapeutic Agents in Tumors-Physiological Barriers and Strategies. J Natl Cancer Inst 81(8):570-576
74. St Croix B, Man S, Kerbel RS. (1998) Reversal of intrinsic and acquired forms of drug resistance by hyaluronidase treatment of solid tumors. Cancer Letters 131(1):35-44
75. Jang SH, Wientjes MG, Au JLS. (2001) Enhancement of paclitaxel delivery to solid tumors by apoptosis-inducing pretreatment: Effect of treatment schedule. J Pharmacol Exp Ther 296(3):1035-1042
76. Kondo A, Maeta M, Oka A, Tsujitani S, Ikeguchi M, Kaibara N. (1996) Hy-potonic intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in mice. Br J Cancer 73(10):1166-1170
77. Elias D, El Otmany A, Bonnay M, Paci A, Ducreux M, Antoun S, Lasser P, Laurent S, Bourget P. (2002) Human pharmacokinetic study of heated intrap-eritoneal oxaliplatin in increasingly hypotonic solutions after complete resection of peritoneal carcinomatosis. Oncology 63(4):346-352
78. Esquis P, Consolo D, Magnin G, Pointaire P, Moretto P, Ynsa MD, Beltramo JL, Drogoul C, Simonet M, Benoit L, Rat P, Chauffert B. (2006) High intra-abdominal pressure enhances the penetration and antitumor effect of intraperi-toneal cisplatin on experimental peritoneal carcinomatosis. Ann Surg 244(1):106-112
79. Jacquet P, Stuart OA, Chang D, Sugarbaker PH. (1996) Effects of intra-abdominal pressure on pharmacokinetics and tissue distribution of doxorubi-cin after intraperitoneal administration. Anticancer Drugs 7(5):596-603